Skip to Main Content

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)

Conditions

Prostate

Phase II

What is the purpose of this trial?

This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).

  • Trial with
    Dana-Farber Cancer Institute
  • Start Date
    06/16/2019
  • End Date
    09/29/2020
Trial Image

For more information about this study, contact:

Jennifer Pope

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/21/2019
  • Study HIC
    #2000023600